title: Lipid based noninvasive vesicular formulation of cytarabine: Nanodeformable liposomes.
abstract: Leukemia is the common cause of death and worldwide incidence of this disease is increasing. Chemotherapy is the first choice for leukemia treatment, but the major limitations of standard therapy are its side effects and poor patient compliances. Therefore it is imperative to look for a therapeutic system with lesser side effects urgently to address the underlying causes of poor treatment outcomes. In such a scenario transdermal route for delivery of chemotherapeutic drugs could be a better alternative to provide sustained drug level, enhanced activity, self administration and better patient compliances. The present work is focus on the design of nanolipid based transdermal carrier, deformable liposomes bearing cytarabine as a model drug for effective delivery of drug with enhanced transdermal flux. Developed nanocarriers were characterized for their size, morphology, entrapment efficiency, skin penetration and irritation. It could be concluded that nanodeformable liposomes accentuated transdermal flux of cytarabine and could provide a new strategy for leukemia.
authors.affiliation: Institute of Pharmaceutical Sciences, Guru Ghasidas Vishwavidyalaya Bilaspur (A Central University), Bilaspur, C.G. 495009, India. Electronic address: rajscientist.2014@rediffmail.com.
authors.forename: Rakesh
authors.initials: R
authors.lastname: Raj
authors.affiliation: Institute of Pharmaceutical Sciences, Guru Ghasidas Vishwavidyalaya Bilaspur (A Central University), Bilaspur, C.G. 495009, India.
authors.forename: Pooja Mongia
authors.initials: PM
authors.lastname: Raj
authors.affiliation: Institute of Pharmaceutical Sciences, Guru Ghasidas Vishwavidyalaya Bilaspur (A Central University), Bilaspur, C.G. 495009, India.
authors.forename: Alpana
authors.initials: A
authors.lastname: Ram
mesh_terms: D000287:Administration, Topical; D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000737:chemistry / Q000493:pharmacokinetics; D003561:Cytarabine / Q000737:chemistry* / Q000493:pharmacokinetics*; D004304:Dosage Forms; D065546:Drug Liberation; D004355:Drug Stability; D008055:Lipids / Q000737:chemistry*; D008081:Liposomes / Q000737:chemistry*; D049329:Nanostructures; D051381:Rats; D017208:Rats, Wistar; D012867:Skin; D012869:Skin Absorption
chemical_list: D000964:Antimetabolites, Antineoplastic; D004304:Dosage Forms; D008055:Lipids; D008081:Liposomes; D003561:Cytarabine
keywords: Cytarabine; Deformable liposomes; Factorial design; Leukemia; Transdermal delivery; Transfersomes